Psychopharmacology Maastricht
The psychopharmacology department at Maastricht University focuses on the cognitive, behavioral, and biological effects of various substances, ranging from pharmaceutical to recreational drugs.
Learn More
Maastricht Psychedelic Symposium
On May 24, the Maastricht Psychedelic Research Team organized a mini-symposium on psychedelics. We welcomed two international speakers: Prof. dos Santos and Prof. Bouso from Brazil and Spain to discuss their ayahuasca and ibogaine research. We also had several internal speakers: presenting on mystical vs. autobiographical psychedelic experiences (Dr Kangaslampi), microdosing (Ms. Haijen), and 5-MeO-DMT (Mr. Reckweg).
Click below to watch the entire symposium
Read about our new paper on the neurological origins of a visual psychedelic hallucination
Congratulations to Zeus Tipado on his newly published paper that introduces a new theory as to why a person experiences a visual trip on psychedelics.
Read The PaperParticipate in our studies!
We're always conducting research in our department and we're frequently looking for participants to be a part of science! If you're interested, look at the studies that we are currently conducting.
View All Studies
Our Scientists
Dr. Conny Quaedflieg
Stress Resilience, Intentional Forgetting, EEG
Through my extensive research experience, I have built expertise in various disciplines (psychology, psychophysiology, neurosciences) and I have become enthusiastic about bridging them.
Mauro Cavarra, MSc
Psychosomatics, Chronic Pain, Psychedelic-Assisted Psychotherapy
I am a psychotherapist, hypnotherapist and clinical trainer interested in understanding the connection between mind and body. At the Department I work in research projects that explore the potential of psychedelic therapies in the treatment...
Henry Whitfeld, MSc
Psilocybin, Psychotherapy, Ideography
After being a psychological therapist with 20years experience in trauma work and mindfulness-informed approaches, I am now a researcher investigating how psychedelic experiences and psychotherapeutic protocols interact.
Dr. Rudy Schreiber
Research Domain Criteria, CNS Drug Discovery
I started my career in central nervous system drug discovery in 1993 and subsequently progressed from bench scientist to senior leadership roles at global pharmaceutical companies
Eline Haijen, MSc
ADHD, Microdosing, Psychedelics
I am a PhD candidate in the Psychopharmacology in Maastricht research group at the Department of Neuropsychology and Psychopharmacology at Maastricht University. I am from a little village close to Maastricht.
Dr. C. Rob Markus
I became an expert on the relation between stress, brain (gene) vulnerability and the development of cognitive-affective complaints/disorders as well as in testing (claims about) dietary treatment/assessment methods.
Dr. Natasha Mason
Psychedelics, Neuroadaptations, Plasticity
My research is driven by my desire to find effective treatments for psychiatric disorders, particularly anxiety, depression, and post-traumatic stress disorder.
Dr. Kim Kuypers
Microdosing, Cognition, Nutrition
My research focuses on the neurobiology of flexible cognition, empathy, and well-being.
Katharina Lege, MSc
Cannabinoids, Neuroimaging, Consciousness
Coming from a background of psychology and clinical neuroscience, I developed a strong interest in altered states of the mind as in mediation or yoga practices.
Psychedelic Research
Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution
Ayahuasca, ego dissolution, cognitive
→
The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides
→
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
→
Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study
→
Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers
→
Cannabis Research
Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users
Cannabis, Cognition, Psychomotor
→
Comparison of Cannabinoid Pharmacokinetic Properties in Occasional and Heavy Users Smoking a Marijuana or Placebo Joint
→
Medicinal Δ9-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests
→
Get in Touch
We are always up for communicating with people that have interesting ideas or questions. If you want to contact our department, please reach out using this form below.